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Background: There is an increasing drive to measure and so improve patients’ experiences 
and outcomes of health care. This also applies to medicines, given their ubiquity as health care 
interventions. Patients’ experiences of using medicines vary, and instruments which measure 
these are seen as an essential component to improve care. We aimed to identify generic measures 
of patients’ experiences of using prescription medicines and to examine their properties and 
suitability for use in research or practice.
Methods: Multiple electronic databases were searched: MEDLINE, Embase, PsycINFO, 
PsycARTICLES, CINHAL Plus, PROQOLID®, and Google Scholar. We identified, criti-
cally appraised, and summarized generic questionnaires assessing one or more aspects of 
the medicine use experience among adult patients using prescription medicines for chronic 
conditions, and the process of questionnaire development, degree of patient involvement, and/
or validation processes.
Results: Fifteen questionnaires were included. Of these, nine measures were multidimensional, 
covering various aspects of medicine use. Six instruments covered only a single domain, 
assessing a specific facet of using medicines. Domains covered were the following: effective-
ness; convenience, practicalities, and/or managing medicines; information, knowledge, and/
or understanding; side effects; relationships and/or communication with health professionals; 
impact on daily living and/or social life; general satisfaction; attitudes; beliefs, concerns, 
and/or perceptions; medical follow-up and/or adherence-related issues; treatment- and/or 
medicine-related burden, perceived control, or autonomy; self-confidence about medicine 
use; availability and accessibility; and medicine-related quality of life. None of the identified 
questionnaires covered all domains. Instruments varied in the extent of patient involvement in 
both their development and validation.
Conclusion: There is a scarcity of psychometrically sound, comprehensive, and generic mea-
sures of experiences of using prescription medicines among adult patients living with chronic 
illnesses. There is a need for further development and/or validation of existing instruments 
suitable for use in this population.
Keywords: prescription medicine, patient experience, questionnaire, patient-reported outcome, 
development, validation
Introduction
Prescribing of medicines is one of the most common health care interventions, and 
monitoring experiences of medicines use is a priority.1 With an increasingly aging 
population, more people are living with multiple chronic illnesses that often demand 
the use of multiple medicines.2
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Although medicines are beneficial, relieving symptoms, 
preventing exacerbations, or even prolonging life, having 
to cope with using regular medicines alongside a long-term 
illness can be challenging but is poorly understood. Chronic 
conditions often necessitate complex self-management 
of both disease effects and medical interventions, which 
impose substantial demands on a patient’s time, effort, and 
finances.3–6 The workload associated with preparing and orga-
nizing regular medicine use and other practical difficulties 
can be burdensome,4 while paying for long-term medicines 
may also cause financial difficulties.7–9
Medicine burden, which is one aspect of treatment bur-
den, can lead to nonadherence and poor clinical outcomes, 
as well as affecting patient satisfaction, psychological well-
being, social functioning, and quality of life.4,6,10 Given the 
growing numbers of people using long-term medicines for 
multiple chronic conditions (polypharmacy),11 the need to 
not only understand but also measure this burden is urgent.
Patients’ experiences of using medicines vary and are 
influenced by a range of factors, including the nature and 
severity of disease condition(s), effectiveness, convenience, 
and impact on general well-being.12–16 Some people are reluc-
tant to use medicines, while others have mixed views through 
weighing potential harmful effects against overall benefits.12,17 
Patients may worry about accessibility and availability, 
medicine-related risks, interactions, or dependence.12,14,16 
Side effects constitute a significantly burdensome aspect of 
treatment,4,6 which can affect patients’ quality of life.10 The 
number of medicines and regimen complexity, including route 
and frequency of administration, and physical properties (eg, 
taste or size of tablet),18 also impact on patients’ experiences.
There is a recognized need for health systems to under-
stand and monitor patients’ experiences, to improve the 
quality of care.19–21 Patient-reported experience measures 
and patient-reported outcome measures are important for 
helping patients judge how they feel about their own experi-
ences and outcomes of care, including the benefits and risks 
of treatment.22
Tools covering medicines use mainly focus on inappro-
priate prescribing,23 identifying potential medicine-related 
problems (including adverse drug reactions [ADRs]),24 and 
adherence.25 Most of these focus on assessing prescriber-
defined outcomes, and hence may not elicit patients’ expe-
riences. Moreover, a recent study has shown that patients’ 
day-to-day difficulties with self-care (including medicine 
use) may be underexplored in practice as clinicians target 
biomedical problems more than socio-behavioral factors, 
such as access or social support.26
Instruments are available which measure how patients 
actually use medicines, although not standardized or vali-
dated,27 as well as assessing individuals’ ability to manage 
medicines.28,29 These are usually administered by health 
professionals or research assistants who assess performance 
of specific tasks, such as identification of medicines (eg, rec-
ognizing packaging or reading the label) and administration 
or use of medicines.28,29 In addition, some use experimental 
simulations rather than patients’ own medicines; actual 
experiences of organizing and using medicines may differ 
from those observed in research settings. One comprehensive 
literature review cited the “lack of a ‘gold standard’ [measure] 
for medication management ability”.29 Furthermore, manag-
ing medicines, as one of the most complex activities of daily 
living,30 is only one aspect of the medicine use experience.
Among instruments which do seek patient experiences, 
measures of satisfaction with treatment dominate the lit-
erature. Many instruments focus on disease-specific31–33 or 
treatment-specific measures of satisfaction.34–37 However, 
given the growing prevalence of multi-morbidity, there is 
an urgent need to understand more about generic measures 
that are potentially applicable across a range of illnesses and 
medicines. Several generic instruments have been devel-
oped to measure satisfaction with medicines38–40 but have 
recently been criticized as measuring only selected aspects 
of medicines use.4,41 To our knowledge, no reviews covering 
generic measures of medicine-related experiences and their 
associated burden have been published. We therefore aimed 
to identify generic measures of patients’ experiences of using 
prescription medicines, assess their content domains, and 
summarize their development and/or validation processes.
Methods
Database search and search strategy
Multiple electronic databases were searched: MEDLINE, 
Embase, PsycINFO, PsycARTICLES, CINHAL Plus, and 
Google Scholar. A manual, free-text, search of the PRO-
QOLID®, a specific database that houses several patient-
related measures, was also conducted. Hand-searching of 
bibliographies of relevant articles was undertaken to identify 
related articles. A 20-year search period, January 1995 to 
April 2015, was selected, based on the publication date of 
an early landmark measure of lay representations and beliefs 
about prescription medicines, the Beliefs about Medicines 
Questionnaire (BMQ).42 This timeframe ensured that relevant 
measures developed in the 5 years before publication of 
the BMQ42 were included. A broad, but sensitive, keyword 
search strategy was employed to identify studies describing 
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the development and/or validation of measures used to assess 
adults’ medicine-related experiences. Categories of search 
terms were combined in a stepwise fashion, and relevant 
search filters were applied to specific publication dates. Sam-
ple categories and search terms used include 1) “medicine” 
or “medication” or “drug” or “prescription” and 2) “patient 
experiences” or “experience*” or “view*” or “perception*” 
or “attitude*” or “belief ” or “concern*”. Categories 1 and 
2 were crossed with search terms in category 3: “question-
naire” or “instrument” or “tool” or “scale” or “measure” or 
“survey*” or “self-report” or “patient reported measure” 
or “develop*” or “valid*”. Neither disease conditions nor 
medicine types were specified. Supplementary material, 
Additional file 1 provides the full search strategy.
inclusion and exclusion criteria
We reviewed studies which involved adults (age ≥18 years) 
using prescription medicines, as children’s ability to self-
report their own experiences differ and instrument develop-
ment processes may also vary.43 Primary research studies 
using a generic (not disease- or treatment-specific), self-
completion instrument on any aspect relating to medicine use 
experiences and describing questionnaire development and/or 
validation in a target population were included. Articles were 
published in English. We excluded the following: studies that 
involved only children or adolescents; studies that primarily 
reported use of over-the-counter medicines or other therapies 
(eg, diet, exercise, or any other aspect of self-care); studies 
that described disease-, product-, and/or device-specific 
measures; studies that used clinician- or pharmacist-reported 
tools for drug-related problems; studies that used tools for 
assessing patients’ ability to manage their medicines; studies 
that described screening tools for assessing inappropriate 
prescribing; studies that used side effect-/ADR-rating scales; 
studies that measured satisfaction with pharmaceutical ser-
vices; studies that primarily assessed adherence; secondary 
validation studies, except if they reported a revised version 
of the instrument; cross-cultural (and language) adaptations 
of eligible questionnaires; and protocols for research.
Article retrieval, data extraction, and 
analysis
All study titles and abstracts were reviewed, discarding 
duplicates. If eligible, the full-text article was scrutinized 
to check for the questionnaire and/or its items (questions). 
Additional searches were conducted if the questionnaire 
was not included in the primary article. Potentially relevant 
studies were screened for inclusion suitability and discussed 
among the research team (BK, SC, JK). Data extraction (by 
BK) from eligible articles was checked and supervised (by 
SC, JK), and regular discussions among all authors were 
held to resolve any issues. The initial literature search was 
conducted in April 2015 and updated in November 2015.
A data extraction form was used to collect the study-
specific (sample size, study population and setting, country 
and language of origin) and questionnaire-specific informa-
tion (name and purpose, number of items, content domain(s) 
and/or subscales, type of response scale, mode of administra-
tion and recall period if specified). Questionnaire derivation, 
particularly the extent of direct patient involvement in item 
generation and testing, and validation methods were reviewed, 
and psychometric properties, such as reliability and different 
forms of validity, were assessed in relation to published crite-
ria.44 Comparison of instruments included domain coverage, 
development history, particularly patient involvement in item 
generation, reliability, and validity. Practical properties, such 
as completion time, were also examined where available.
Standards and guidance state that documentation of an 
instrument’s development history is fundamental.22,45 This 
includes item generation and testing of how well patients 
understand questionnaire items and response options and 
the appropriateness of the measure to the patient group,46,47 
helping to assess face and content validity, alongside 
researchers and expert panels.44 Records of measurement 
(or psychometric) properties, particularly reliability and 
validity, also provide evidence that an instrument measures 
what it claims.22,44,45 Other characteristics, such as mode of 
questionnaire administration and the time period over which 
a participant is requested to reflect (recall period), content 
domains, number of items and their response options, and 
the population and setting used also impact on instrument 
validity.45
Construct validation of underlying theoretical concepts 
and domains in a questionnaire can be conducted using dif-
ferent methods, scale analysis (through exploratory and/or 
confirmatory factor analysis, item-total correlations [adequate 
if >0.20]48 and floor–ceiling effects that explore lowest or 
highest possible scores) and convergent and discriminant 
(or divergent) validations, which explore relationships with 
conceptually similar and dissimilar reference instrument(s), 
respectively.44,48 Correlations ≥0.3 may support convergent 
validity, whereas a trend of low correlations may infer discrim-
inant validity.48 Both convergent and discriminant validations 
are aspects of criterion-related validation, in which scores 
of new questionnaires (or those undergoing development) 
are compared with established ones (or “gold standards”); 
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 correlations of at least 0.70 with a “gold standard” measure 
may confirm criterion-related validity.44 Other aspects of 
criterion-related validity, such as predictive validation, test an 
instrument’s ability to predict associations or differences in 
certain variables in the expected direction.49 Known-groups 
validity examines an instrument’s ability to differentiate 
cohorts of patients with well-known characteristics.48
Results
Identified generic measures of medicine 
use experiences
Fifteen articles described the development and/or valida-
tion of generic measures relating to the experience of using 
prescription medicines among adult patients.
Of these, nine were multi-domain (three to ten domains), 
five of which examined satisfaction with different aspects of 
using medicines: three versions of the Treatment Satisfaction 
Questionnaire for Medication (TSQM; TSQM version 1.4,39 
TSQM II,38 and TSQM-950), the Treatment Satisfaction with 
Medicines Questionnaire (SATMED-Q40), and the Patient 
Satisfaction with Medication Management instrument 
(PSMM51). Other multi-domain instruments were the Drug 
Therapy Concerns Questionnaire (DTC52), the Okere–Reiner 
Survey,53 the Living with Medicines Questionnaire (LMQ54), 
and the Patient-Reported Outcomes Measure of Pharmaceuti-
cal Therapy for Quality of Life (PROMPT-QoL41).
Six instruments covered only one domain, although some 
of these were divided into subscales by statistical analyses: a 
unidimensional measure of treatment burden (the Treatment 
Burden Questionnaire [TBQ]55), a questionnaire assessing 
patients’ attitudes to deprescribing or medicine cessation 
(Patients’ Attitudes Towards Deprescribing [PATD]56), the 
BMQ42, a measure of perceived sensitivity to medicines 
(Perceived Sensitivity to Medicines questionnaire [PSM]57), 
the Satisfaction with Information about Medicines Scale 
(SIMS58), and questionnaires measuring doctor–patient com-
munication about medicines.59
Most of the questionnaires identified were self-adminis-
tered on 3- to 10-point Likert-type scales. All instruments 
were multi-item, ranging from five to 60 items per question-
naire. The majority were developed in English, originating 
from the UK, USA, and Australia, with only three40,41,55 from 
non-English-speaking countries: Spain, Thailand and France. 
Table 1 summarizes the characteristics of the 15 instruments.
Content domains
The 15 instruments covered a wide range of domains 
(Table 2), described by authors as the following:  effectiveness; T
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Measuring medicine-related experiences
convenience, practicalities, and/or managing medicines; 
information, knowledge, and/or understanding; side effects; 
relationships and/or communication with health profession-
als; impact on daily living and/or social life; general satisfac-
tion; attitudes; beliefs, concerns, and/or perceptions; medical 
follow-up and/or adherence-related issues; treatment- and/
or medicine-related burden, perceived control, or autonomy; 
self-confidence about medicine use; availability and acces-
sibility; and medicine-related quality of life. These probably 
reflect most issues that affect people using regular medicines.
Patient involvement in item generation
For the majority of instruments, item generation was based 
on the literature. Some incorporated patients’ views but indi-
rectly. Only seven measures had evidence of being developed 
using direct patient input: five employed patient interviews as 
the primary source of questionnaire items (BMQ,42 PSMM,51 
TBQ,55 LMQ,54 and PROMPT-QoL41) and two focus groups 
(SATMED-Q40 and TSQM version 1.439). Several were 
judged to emphasize the perspective/opinions of researchers 
or health professionals over those of patients (Jenkins’ instru-
ment,59 SIMS,58 and DTC52). Table 3 compares the different 
methods employed in item generation and testing.
Reliability
The vast majority of instruments were assessed for internal 
consistency (Table 4), mostly using Cronbach’s alpha with 
some reporting test–retest reliability as intra-class correla-
tion coefficient and correlation coefficients (r); values ≥0.7, 
obtained from a sample size of at least 50 patients, are 
advisable.44 One study41 employed Rasch analysis to estimate 
person and item reliabilities (acceptable values >0.8 and 0.9, 
respectively), which assess an instrument’s ability to distin-
guish between high and low patient scores and the level of 
item difficulty, respectively.60
Scale analysis and construct validity
Most instruments employed exploratory techniques for scale 
analysis (Table 4). However, only a few employed confirma-
tory methods ascertaining underlying content domains and/or 
their relationships: TSQM II, TSQM-9, SATMED-Q, BMQ, 
and the Okere–Reiner Survey.
Criterion-related, convergence, and/or 
discriminant validity
Criterion-related, convergence, and/or discriminant validity 
were variably reported by only eight instruments: TSQM 
(version 1.4), TSQM II, SATMED-Q, TBQ, SIMS, BMQ, T
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PSM, and PATD (Table 4). The BMQ42 and earlier versions 
of the TSQM38,39 were the most commonly used criterion-
referenced instruments. For instance, in validating the SIMS, 
patients with stronger concerns about medicines as measured 
by the BMQ were more likely to be less satisfied with their 
medicine information. Patients with more medicine-related 
concerns, or beliefs about harm, were reported to not only 
be less trustful of their medicines but also desire altera-
tions to their regimes or avoid them.42 In development of 
the PSM scale, scores on the “concerns” subscale of the 
BMQ, indicating negative beliefs about medicines, were sig-
nificantly associated with perceived sensitivity to medicines 
(r=0.5, P<0.001). Negative moderate correlations (r=–0.56, 
P<0.001) were reported between scores on BMQ items relat-
ing to “necessity of current medications” and scores on the 
PATD. However, the sample size used in this study (n=51) 
was inadequate to validate the measure of patient attitudes 
to medicine cessation.
Ruiz et al examined associations between SATMED-Q 
scores and the Spanish version of the TSQM (version 1.4); 
significant correlations (range 0.58–0.68, P<0.0005) were 
reported between subscales assessing similar domains: 
treatment effectiveness, side effects, convenience, and 
global satisfaction.40 During validation of the TBQ, Tran 
et al established a negative relationship between treatment 
burden and treatment satisfaction assessed using the TSQM 
II:55 moderate negative correlations between TBQ scores 
and TSQM global satisfaction and convenience subscales 
(r=–0.41 and r=–0.53, respectively) and weak negative cor-
relations (r=–0.26) between TBQ scores and TSQM efficacy 
subscale. Treatment burden was significantly higher among 
patients who had experienced side effects compared to those 
who had not.
Satisfaction with medicines is positively associated 
with adherence.50 While validating the TSQM-9, moder-
ate correlations (range 0.34–0.46) were reported between 
convenience, effectiveness, and global satisfaction TSQM-9 
subscale scores, and the modified Morisky scale,61 which 
measures adherence. Weak correlations (range 0.09–0.22) 
were reported between SATMED-Q scores and Morisky–
Green adherence questionnaire scores,62 several failing to 
reach statistical significance.
Known-groups and predictive validity
Known-groups validity was reported for six measures: 
BMQ, TSQM version 1.4, TSQM II, TSQM-9, TBQ, and the 
Okere–Reiner Survey (Table 4). The Okere–Reiner Survey 
was reported to “clearly distinguish between patients with 
good and poor perceived knowledge or confidence or satisfac-
tion”.53 Least reported was predictive validity (Table 4). The 
BMQ was reported to adequately distinguish patients with 
different illnesses and treatments42 and to predict adherence 
to therapy.63 In validating the TSQM (version 1.4), Atkinson 
et al tested associations between medicine types and routes of 
administration and satisfaction levels on all four subscales; 
patients using parenteral medicines were least satisfied 
with convenience and side effects, while oral medicines 
were rated highly on overall satisfaction and convenience.39 
Similarly, Ruiz et al reported significantly lower satisfac-
tion for convenience for parenteral routes of administration 
compared to oral and inhalation routes.40 Treatment satisfac-
tion assessed by TSQM-9 was significantly greater among 
“medium compliers”, measured by the modified Morisky 
scale,61 compared to “low compliers” (P<0.0001). Tran et al 
reported significantly higher scores among patients with 
high treatment burden, measured by the TBQ, compared to 
those with low or moderate treatment burden, on specific 
items relating to treatment workload.55 Patients with “high 
burden” needed an average of 43 minutes/week to organize 
their medicines compared to 17 minutes/week required by 
“low-burden” patients (P<0.0001).55
Summary
Of the 15 generic measures of medicine-related experiences, 
six covered multiple domains and were developed with direct 
patient involvement, particularly in the item generation phase, 
tested for any forms of reliability (as internal consistency, 
test–test, and/or person/item reliability), and/or attempted to 
confirm construct validity by any means. These were TSQM 
(including the 14-item, eleven-item, and nine-item versions), 
SATMED-Q, PROMPT-QoL, and LMQ. However, validity 
was reported using different methods and to different extents 
for all these measures, and most authors acknowledge the 
need for further developmental and/or validation work. The 
two broadest, patient-generated, multi-domain measures, 
the PROMPT-QoL41 and the LMQ,54,64 may provide insight 
into measurement of multiple, albeit complex, issues sur-
rounding regular medicine use; however, both require further 
psychometric testing (and/or cross-cultural adaptation) for 
potential use in research or practice. None of the identified 
questionnaires covered all domains or considered potential 
financial burden of medicines in-depth.
The remaining instruments cover single domains or have 
limited patient involvement in development. The BMQ,42 one 
of the earliest measures of beliefs about medicines, has been 
used widely to understand many aspects of medicine use, 
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especially adherence-related behavior. The DTC52,65 serves 
as a potentially useful tool for eliciting patients’ perceptions 
and concerns about medicine-related problems; however, it 
lacked patient involvement in item generation phases of its 
development. The domain-specific PSM scale57 may be use-
ful for studies evaluating concerns about potential adverse 
effects of medicines. The Okere–Reiner Survey53 is a short 
measure of patients’ knowledge and self-confidence with 
medicine use, the latter aspect not being included in other 
instruments, which play an important role in the medicine 
use experience; however, it was not derived directly from 
patients despite testing instrument reliability and validity. 
The PSMM,51 an instrument reported to measure patients’ 
perceptions of medicine management, is prescriber-centered 
and focused on service evaluation, despite being derived 
directly from patient interviews and including relevant issues. 
For instance, it considers the practicalities of managing regu-
larly used medicines while in hospital, medicine information, 
and understanding and patient–provider communication 
about medicines. The latter aspect was the subject of the 
scale developed by Jenkins et al.59 The PATD questionnaire56 
considers deprescribing (medicine cessation), and may be 
used to gain insight into patient preferences or dissatisfac-
tion with medicine regimes; however, further validation of 
this instrument is also necessary, as it was developed from 
the perspective of health professionals and evaluated in only 
a few patients. Although domain-specific and not solely 
focused on medicine–therapeutic interventions, the TBQ55 
is potentially useful in assessing treatment burden among 
multi-morbid patients.
Discussion
To our knowledge, this is the first review of generic measures 
of adult patients’ experiences of using prescription medicines. 
Most of the 15 instruments identified could potentially be 
used in patients with multi-morbidity, using a wide range 
of medicines, allowing comparison of experiences across 
different patient groups. However, those which instruct 
respondents to focus only on one medicine40 would require 
modification. Only a few directly involved patients in item 
generation, and further validation work is needed, particularly 
for those instruments covering multidimensional aspects of 
medicine use.
Collectively, the domains covered probably reflect most 
issues that affect people using regular medicines. However, 
none covered all domains, which is important if a whole 
patient-centered understanding of medicine experiences is 
to be quantified. Notably, none of the instruments considered 
the potential financial burden of using prescription medicines 
in any depth. One of the broad instruments, PROMPT-QoL, 
includes one item on “medication and travel expenses”41 
which is limited as an assessment of cost-related burden. 
An item in the PATD questionnaire, “having to pay for less 
medications would play a role in my willingness to stop one 
or more of my medications”, only focuses on cost-related 
cessation.56 One recently developed, ten-item, domain-
specific measure of cost-related medicine burden in the US 
population8 explores this issue in isolation. However, it was 
not included in this review as half the statements relate to 
nonadherence (eg, cost-related delays in refilling prescrip-
tions and skipping or reducing doses).8 There remains a need 
for instruments that incorporate and assess cost-related issues 
alongside other dimensions of the medicine use experience.
Overall satisfaction with medicines could be regarded as 
a potentially key, overarching domain, which is influenced by 
many of the other domains covered by these instruments and 
was the main focus of several questionnaires. Of the generic 
instruments, TSQM (version 1.4 and II)38,39 and SATMED-Q40 
seem promising for evaluating aspects of medicine use which 
impact on satisfaction. However, both have been criticized as 
circumscribed and lacking in “psychological domains, such 
as worry, fear, or concerns”, relating to the medicine use 
experience,41 which are covered by the broader instruments.
Patient satisfaction with treatment (and medicines) is 
positively associated with persistence and adherence to 
therapy66 but negatively associated with treatment bur-
den.55 Lifelong medicine use can be burdensome to some 
patients,13–15 and may impact negatively on health-related 
quality of life. Research attempting to describe the burden 
(or negative experience) of using medicines has done so 
under the “umbrella” of treatment burden,4,6,67,68 which 
may represent unshared patient experiences that are not 
fully addressed during consultations.26 However, measures 
of treatment burden are currently limited, as reported in a 
review by Eton et al.5 In contrast to the present review, Eton 
et al focused on the overall burden of health care activities, 
particularly patients’ workload of self-care. An instrument 
addressing the need for such a measure, the TBQ,55 includes 
some aspects of medicine-related burden, as well as impact 
or restriction of daily activities and social life. Other poten-
tially useful multi-domain measures of medicine burden 
are the LMQ, which is still undergoing development in the 
UK,54 and the PROMPT-QoL,41 which also requires further 
psychometric testing.
Communication and relationships with health care pro-
viders was an aspect of medicines use included in a number 
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of instruments, including the two broadest, patient-centered 
measures, PROMPT-QoL41 and LMQ,54 emphasizing the 
potential contribution of this domain to satisfaction and 
treatment burden. The PSMM questionnaire51 also includes 
patient–provider communication problems, for instance, 
perceived patient burden following repetitive questioning 
about medicine history, often by multiple providers, and 
ineffective flow of medicine-related information among 
health professionals.53 Most measures of patient satisfaction 
with consultations and patient–provider relationships69–71 do 
not focus on medicine-related communication; hence, the 
instrument developed by Jenkins et al is potentially valuable 
as a single-domain measure.59 Two other instruments, the 
SIMS58 and the Okere–Reiner Survey,53 also cover medicines 
information transfer. The SIMS focuses on this exclusively 
and is founded on pharmaceutical industry literature, with 
minimal patient involvement, while the Okere–Reiner Survey 
measures medicine-related knowledge and understanding but 
again had little patient involvement during its development.
Many other instruments reviewed were essentially unidi-
mensional, with variable patient involvement in development. 
The BMQ, which assesses psychological beliefs and concerns 
about the necessity and safety of medicines,42 has been exten-
sively used in adherence-related studies.72,73 The PSM scale 
covers only patient concerns about potential adverse effects 
of medicines,57 while the PATD was developed to measure 
patients’ attitudes to cessation of medicines,56 and thus seeks 
to predict behavior, rather than measure experiences. Like 
most instruments assessing inappropriate prescribing,23 the 
PATD questionnaire development seemed to emphasize the 
clinician perspective, rather than the patient perspective. 
Moreover, deprescribing itself is criticized as a clinician-
driven agenda, which aims to reduce medicine usage and 
health-system costs.74,75 The DTC is broader, including 
concerns about ADRs, as well as regimen complexity, over-
medication, and use of prescription medicines,52 but also 
based on the clinician perspective.
A further instrument, developed in Taiwan and published 
since the literature review was completed, claims to measure 
Medication-Related Quality of Life,76 a term originally 
adopted for the LMQ.77 This instrument was developed based 
on subjective well-being scales plus patient interviews and 
consists of 14 items, covering only three domains: role limita-
tions, self-control, and vitality.76 Only the first of these relates 
directly to medicines burden, as discussed in this review; 
therefore, this instrument too is limited.
Most instruments included in this review were developed 
and tested in a specific language and in specific demographic 
settings, and with some exceptions, have not been tested in 
other situations. Therefore, cross-cultural adaptations and/
or further testing may be required prior to use in particular 
clinical or research settings. Given the psychometric proper-
ties of the reviewed instruments, there is a need for further 
development and/or validation of the existing multidimen-
sional, generic, patient-generated, measures of experiences 
of using prescription medicines among adult patients living 
with chronic illness.
implications for research and practice
Multidimensional, generic, patient-generated measures are 
essential to evaluate the impact of interventions designed to 
reduce treatment burden or improve experiences, particularly 
in the context of multi-morbidity and complex medicines 
regimes. Such measures could facilitate the identification of 
patients who find using long-term medicines a challenging 
experience. This could enable health care professionals to 
offer tailored support or to more effectively agree treatment 
tailored to patients’ needs. However, little is known about the 
use of most of these instruments in clinical practice. There is 
therefore a need to identify and fully validate the best avail-
able patient-generated instruments, to facilitate such use. 
Should a need to develop and test new instruments arise, 
adding key, albeit deficient, content domains to existing mul-
tidimensional measures may support a more comprehensive 
assessment of medicine use experiences among those living 
with chronic illness.
Limitations
Owing to the heterogeneity of studies and reported results, 
data could neither be evaluated methodologically (as with 
most systematic reviews) nor be collated for meta-analysis. 
Although we used relevant guidelines to critique the reported 
measurement properties of questionnaires,44 we did not set 
out to report an overall quality score for the instruments and 
their methodological study designs, particularly as many of 
the instruments were developed long before the recently rec-
ommended quality-scoring criteria.78–80 Therefore, this review 
employed a descriptive style to compare characteristics, 
content areas, and questionnaire derivation and validation 
processes across reviewed measures. It excluded all disease-, 
product-, and/or device-specific instruments, pharmaceutical 
service evaluations, clinician- and pharmacist-led screening 
tools for medicine-related problems, including ADRs, tools 
assessing patients’ abilities to manage medicines, adherence-
focused tools, and cross-cultural adaptations of eligible ques-
tionnaires, even though they may have considered key aspects 
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of the medicine use experience. It did include measures of 
satisfaction with various aspects of medicine use, despite 
concerns that measuring patients’ experiences in terms of 
satisfaction may introduce acquiescence bias. Although an 
organized and broad literature search was conducted across 
multiple databases, it is possible that a few generic instru-
ments reporting certain aspects of medicine-related experi-
ences may have been missed. Appropriate search strategies 
were designed to minimize the likelihood of this.
Conclusion
There is a scarcity of generic, patient-generated, psychometri-
cally sound, comprehensive measures of the medicine use 
experiences of adult patients. Moreover, there is insufficient 
evidence for the routine use of existing measures in clinical 
practice. Therefore, there is a need for further development 
and/or validation of existing patient-derived, multi-domain 
instruments. In addition to their use in research, such tools 
may help individual patients to identify a range of medicine-
related issues that impact on their day-to-day life and thus 
facilitate conversations with health providers in addressing 
those issues.
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